Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo

American Journal of Hematology

Volumn 84, Issue 5, 2009, Pages 268-272

  Edwards, Claire M ^a   Lwin, Seint T ^a   Fowler, Jessica A ^a   Oyajobi, Babatunde O ^b   Zhuang, Junling ^a   Bates, Andreia L ^a   Mundy, Gregory R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW; BONE TISSUE; CANCER GROWTH; CELL ISOLATION; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MICROENVIRONMENT; MOUSE; MYELOMA; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; BONE MARROW; BONE MARROW CELLS; BORONIC ACIDS; CELL COMMUNICATION; CELL LINE, TUMOR; ENZYME ACTIVATION; IMMUNOGLOBULIN G; MICE; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TUMOR BURDEN;

EID: 65649154116     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21374     Document Type: Article

References (25)

1. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
2. LeBlanc R, Catley LP, Hideshima T, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002;62:4996-5000.
3. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-1534.
4. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
5. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
6. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
7. Cenci S, Mezghrani A, Cascio P, et al. Progressively impaired proteasomal capacity during terminal plasma cell differentiation. Embo J 2006;25:1104-1113.
8. Meister S, Schubert U, Neubert K, et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 2007;67:1783-1792.
9. Busse A, Kraus M, Na IK, et al. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits. Cancer 2008;112:659-670.
10. Jakob C, Egerer K, Liebisch P, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood 2007;109:2100-2105.
11. Wada M, Kosaka M, Saito S, et al. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med 1993;121:215-223.
12. Mundy GR, Raisz LG, Cooper RA, et al. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291:1041-1046.
13. Edwards CM, Zhuang J, Mundy GR. The pathogenesis of the bone disease of multiple myeloma. Bone 2008;42:1007-1013.
14. Garrett IR, Chen D, Gutierrez G, et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003;111:1771-1782.
15. Giuliani N, Morandi F, Tagliaferri S, et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007;110:334-338.
16. Oyajobi BO, Garrett IR, Gupta A, et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: Implications for myeloma bone disease. Br J Haematol 2007;139:434-438.
17. Terpos E, Heath DJ, Rahemtulla A, et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006;135:688-692.
18. Ozaki S, Tanaka O, Fujii S, et al. Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma. Int J Hematol 2007;86:180-185.
19. Altun M, Galardy PJ, Shringarpure R, et al. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res 2005;65:7896-7901.
20. Radl J, de Glopper E, Schuit HER, Zurcher C. Idiopathic paraprotienemia:II. Transplantation of the paraprotein-producing clone from old to young C587Bl/KaLwRij mice. J Immunol 1979;122:609-613.
21. Dallas SL, Garrett IR, Oyayobi BO, et al. Ibandronate reduces osteolytic lesions but not tumour burden in a murine model of myeloma bone disease. Blood 1999;93:1697-1706.
22. Oyajobi BO, Franchin G, Williams PJ, et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 2003;102:311-319.
23. Edwards CM, Edwards JR, Lwin ST, et al. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo. Blood 2008;111:2833-2842.
24. Oyajobi BO, Munoz S, Kakonen R, et al. Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging. Mol Cancer Ther 2007;6:1701-1708.
25. Pennisi A, Li X, Ling W, et al. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009;84:6-14.